BioSpace News Archive

Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez , the company’s president and chief executive officer, is scheduled to participate in a panel discussion on COVID-19 during Citi’s 15 th Annual BioPharma Virtual Conference taking place September 9-10, 2020 . Citi Panel Details: Pa

Boehringer Ingelheim today announced the final analysis from GioTag, a real-world retrospective, observational study

The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment

Tottenham Acquisition I Limited (“Tottenham”) (NASDAQ: TOTA TOTAU, TOTAW, TOTAR), a special purpose acquisition company, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) for a business combination with Clene Nanomedicine, Inc. (“Clene”),

Belmont University, University of New Haven, Illinois State University, Virginia Tech, University of Memphis are 2020 top fundraising schools

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following upcoming virtual investor conferences in September: Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in a panel presentation at the Citi 15th Annual BioPhar

Protara Therapeutics, Inc., a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 27,500 shares of common stock to two new employees.

PLANTATION, FL, Sept. 2, 2020 /PRNewswire/ - Akumin Inc. announced that its common shares have been approved for listing and trading in U.S. dollar currency on the Nasdaq Capital Market.

Natera, Inc., a pioneer and leader in cell-free DNA testing, announced the unblinding of the SMART clinical trial data, and the validation of an artificial intelligence-based platform as part of its Panorama non-invasive prenatal test.

Telix Pharmaceuticals Limited announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform.